Advent Bioservices

Advent Bioservices is a private, pre-revenue CDMO positioned in the UK's 'golden triangle' for cell and gene therapy. Its core strategy is to build and operate a new, flexible GMP facility to provide scalable manufacturing and development services to therapy developers, addressing a critical bottleneck in the industry. The company emphasizes regulatory expertise, a partnership-focused model, and a senior team with deep experience in cellular therapy to capture market share in the rapidly expanding ATMP sector.

Adaptable GMP manufacturing infrastructure and operational systems for cell and gene therapies, including multiproduct cleanroom suites, integrated eQMS/eBMR/LIMS, and cryogenic storage services.

Advent competes in the crowded cell therapy CDMO space against large multinationals (e.g., Lonza, Catalent, Thermo Fisher) and other specialized players (e.g., Oxford Biomedica, Cell and Gene Therapy Catapult). Differentiation will rely on its UK focus, modern facility, partnership model, and senior team's deep therapeutic expertise.